{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+%28Xtandi%29&page=2", "query": { "intervention": "Enzalutamide (Xtandi)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 289, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+%28Xtandi%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enzalutamide+%28Xtandi%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T02:17:29.070Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03709550", "title": "Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma in the Soft Tissue", "Prostate Carcinoma Metastatic in the Bone", "PSA Level Greater Than or Equal to Two", "PSA Progression", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2021-04-15", "completion_date": "2024-04-15", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709550" }, { "nct_id": "NCT03939689", "title": "I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Castration-resistant Prostate Cancer", "Prostatic Neoplasm", "Cancer of the Prostate", "Progressive mCRPC" ], "interventions": [ { "name": "I-131-1095", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progenics Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2019-05-30", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 20, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03939689" }, { "nct_id": "NCT02269982", "title": "Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AR-v7 assays", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2015-05-14", "completion_date": "2019-04-30", "has_results": false, "last_update_posted_date": "2019-06-10", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 5, "location_summary": "Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269982" }, { "nct_id": "NCT06551324", "title": "A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castrate Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "PF-06821497", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 600, "start_date": "2024-10-21", "completion_date": "2028-10-29", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 70, "location_summary": "Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06551324" }, { "nct_id": "NCT07406282", "title": "A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms", "Metastatic Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1400, "start_date": "2025-07-22", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07406282" }, { "nct_id": "NCT01927627", "title": "Enzalutamide in Patients With High-risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 42, "start_date": "2013-11-11", "completion_date": "2017-04-26", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01927627" }, { "nct_id": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant with Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 32, "start_date": "2017-07-06", "completion_date": "2020-04-10", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 3, "location_summary": "Aurora, Colorado • Lone Tree, Colorado • Germantown, Tennessee", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953860" }, { "nct_id": "NCT01091103", "title": "Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Progressive Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2010-02-18", "completion_date": "2013-08-31", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01091103" }, { "nct_id": "NCT06576037", "title": "Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "CBP-1019", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FLUOROURACIL", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2024-10-31", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06576037" }, { "nct_id": "NCT06136624", "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1310, "start_date": "2023-12-31", "completion_date": "2030-02-15", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-06T02:17:29.070Z", "location_count": 48, "location_summary": "Orange, California • Palo Alto, California • Riverside, California + 41 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136624" } ] }